Altimmune
ALT
72 hedge funds and large institutions have $289M invested in Altimmune in 2020 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 15 closing their positions.
102% more capital invested
Capital invested by funds: $143M → $289M (+$146M)
100% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 15
26% more funds holding
Funds holding: 57 → 72 (+15)
26.04% more ownership
Funds ownership: 40.5% → 66.54% (+26%)
23% more call options, than puts
Call options by funds: $5.71M | Put options by funds: $4.64M
20% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$40M |
| 2 |
D.E. Shaw & Co
New York
|
+$33.2M |
| 3 |
AC
Armistice Capital
New York
|
+$28.7M |
| 4 |
RI
RTW Investments
New York
|
+$26.7M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$17.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$8.35M |
| 2 |
Millennium Management
New York
|
-$4.56M |
| 3 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
-$4.23M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.24M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.48M |
ALT Hedge Fund Activity: Q3 2020 in Review
72 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q3 2020, worth a combined $289M — up 102% from $143M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ALT positions and 15 closed out — a net gain of 15 holders — while 18 added to existing stakes and 15 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $40M. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $8.35M sold.
- 72 institutional investors held Altimmune (ALT) as of Q3 2020, up from 57 in Q2 2020.
- Funds reported $289M of Altimmune stock for Q3 2020, up 102% quarter-over-quarter.
- 30 funds opened new Altimmune positions in Q3 2020 and 15 closed out, a net change of +15 holders.
- The largest Altimmune buyer in Q3 2020 was Avoro Capital Advisors, an estimated $40M added.
- The largest Altimmune seller in Q3 2020 was Hudson Bay Capital Management, an estimated $8.35M sold.
Based on aggregated 13F filings for Q3 2020.